Global Orphan Drugs Market Outlook 2020
|発行||RNCOS E-Services Pvt. Ltd.||商品コード||349903|
|出版日||ページ情報||英文 64 Pages
|希少疾患用医薬品の世界市場の将来展望 Global Orphan Drugs Market Outlook 2020|
|出版日: 2016年01月01日||ページ情報: 英文 64 Pages||
希少疾患用医薬品 (希用薬) は別名「ニッチ・バスター」とも呼ばれ、まだ満足な治療法が見つかっていない希少疾患の患者を治療するために開発・製造されたものです。治療法がまだ無い希少疾患の患者は全世界で4000〜5000人にすぎませんが、ブロックバスター薬の特許満了やジェネリック医薬品との競合を受けて、製薬業界では希少疾患治療薬の開発に乗り出しつつあります。各国政府からの支援もまた、市場成長の一因となっています。希少疾患用医薬品の世界市場は、2020年には1億8000万米ドルの規模に達する見通しです。
当レポートでは、世界の希少疾患用医薬品 (オーファンドラッグ) の市場について分析し、市場の全体的構造や促進・抑制要因、市場全体および種類別・地域別・用途別の動向見通し、治験中のパイプライン製品の情報、今後の製品開発・市場成長の方向性、主要企業のプロファイルと製品概要などについて調査しております。
Orphan drugs, also called niche busters, are intended to treat patients suffering from very serious diseases for which no treatment or at least a satisfactory one, has so far been available. These diseases, often referred to as orphan diseases or rare diseases, affect only a small portion of the population. The number of diseases for which no treatment is currently available is estimated to be between 4,000 to 5,000, worldwide. The patent expiry of blockbuster drugs and increased competition from generics has shifted the focus of pharmaceutical industry from the essential medicines to orphan drugs. Incentives for drug development provided by governments, as well as support from the regulatory bodies, are a further boost for the companies developing orphan drugs all over the world.
According to the report “Global Orphan Drugs Market Outlook 2020”, the orphan drug market is anticipated to reach around US$ 180 Billion by 2020. The report provides a detailed analysis of the market for these orphan drugs. An estimation of the market potential of these drugs has been done keeping in mind that many more of these drugs are being tested in clinical trials for various indications, apart from the ones that are already approved. Furthermore, the report also provides the revenue generated by top 10 orphan drugs in 2014.
The report provides information about the segments of the orphan drug market on the basis of type, geography, and therapeutic application. It also highlights orphan drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth. The regulatory scenario of orphan drug industry across different geographic regions of the world has also been discussed in the report.
The later part of the report discusses some of the prominent players in the global orphan drug market. A brief business overview of each player has been provided along with their business segments, product portfolios, and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.